AU2010266120B2 - Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections - Google Patents

Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections Download PDF

Info

Publication number
AU2010266120B2
AU2010266120B2 AU2010266120A AU2010266120A AU2010266120B2 AU 2010266120 B2 AU2010266120 B2 AU 2010266120B2 AU 2010266120 A AU2010266120 A AU 2010266120A AU 2010266120 A AU2010266120 A AU 2010266120A AU 2010266120 B2 AU2010266120 B2 AU 2010266120B2
Authority
AU
Australia
Prior art keywords
finafloxacin
compositions
composition
otic
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010266120A
Other languages
English (en)
Other versions
AU2010266120A1 (en
Inventor
Kenneth C. Appell
Masood A. Chowhan
David W. Stroman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curofin Pharma GmbH
Original Assignee
Curofin Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42752088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010266120(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curofin Pharma GmbH filed Critical Curofin Pharma GmbH
Publication of AU2010266120A1 publication Critical patent/AU2010266120A1/en
Application granted granted Critical
Publication of AU2010266120B2 publication Critical patent/AU2010266120B2/en
Assigned to MERLION PHARMACEUTICALS, PTE., LTD. reassignment MERLION PHARMACEUTICALS, PTE., LTD. Request for Assignment Assignors: ALCON RESEARCH, LTD.
Assigned to MERLION PHARMACEUTICALS GMBH reassignment MERLION PHARMACEUTICALS GMBH Request for Assignment Assignors: MERLION PHARMACEUTICALS, PTE., LTD.
Assigned to CUROFIN PHARMA GMBH reassignment CUROFIN PHARMA GMBH Request for Assignment Assignors: MERLION PHARMACEUTICALS GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010266120A 2009-07-02 2010-07-02 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections Active AU2010266120B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22262509P 2009-07-02 2009-07-02
US61/222,625 2009-07-02
PCT/US2010/040956 WO2011003091A1 (en) 2009-07-02 2010-07-02 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections

Publications (2)

Publication Number Publication Date
AU2010266120A1 AU2010266120A1 (en) 2012-02-02
AU2010266120B2 true AU2010266120B2 (en) 2014-02-06

Family

ID=42752088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010266120A Active AU2010266120B2 (en) 2009-07-02 2010-07-02 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections

Country Status (17)

Country Link
US (3) US8536167B2 (enExample)
EP (1) EP2448587B1 (enExample)
JP (2) JP5784012B2 (enExample)
KR (1) KR101541823B1 (enExample)
CN (2) CN102470139A (enExample)
AR (1) AR077372A1 (enExample)
AU (1) AU2010266120B2 (enExample)
BR (1) BRPI1016257B8 (enExample)
CA (1) CA2765852C (enExample)
CL (1) CL2011003327A1 (enExample)
ES (1) ES2694775T3 (enExample)
MX (1) MX2012000136A (enExample)
RU (1) RU2570731C2 (enExample)
TW (1) TWI460181B (enExample)
UY (1) UY32758A (enExample)
WO (1) WO2011003091A1 (enExample)
ZA (1) ZA201109492B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5784012B2 (ja) * 2009-07-02 2015-09-24 アルコン リサーチ， リミテッド 眼、耳または鼻の感染症を処置するためのフィナフロキサシンを含む組成物および方法
US20150174137A1 (en) * 2010-06-02 2015-06-25 Alcon Research, Ltd. Compositions for treating microbial infections
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
HK1221151A1 (zh) * 2013-08-12 2017-05-26 Novartis Ag 用於治疗鼓膜造孔插管放置後的耳部感染的方法
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
DE102015100068A1 (de) 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen
US11529309B2 (en) * 2016-04-29 2022-12-20 University Of Houston System Compositions, methods and kits for treating a contact lens
US10282607B2 (en) 2016-10-28 2019-05-07 The Nielsen Company (Us), Llc Reducing scale estimate errors in shelf images
WO2023052871A2 (en) 2021-09-28 2023-04-06 Alcon Inc. Otological surgery under perfluorocarbon liquids

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133260A (en) * 1996-12-16 2000-10-17 Bayer Aktiengesellschaft Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
WO2001089496A2 (en) * 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832535B2 (ja) * 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
JP2006289070A (ja) * 2005-03-18 2006-10-26 Santen Pharmaceut Co Ltd キノロン系抗菌化合物含有製品
HUE030419T2 (en) * 2005-05-18 2017-05-29 Horizon Orphan Llc Aerosolized fluoroquinolones and their uses
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP5784012B2 (ja) * 2009-07-02 2015-09-24 アルコン リサーチ， リミテッド 眼、耳または鼻の感染症を処置するためのフィナフロキサシンを含む組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133260A (en) * 1996-12-16 2000-10-17 Bayer Aktiengesellschaft Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
WO2001089496A2 (en) * 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics

Also Published As

Publication number Publication date
EP2448587B1 (en) 2018-08-22
WO2011003091A1 (en) 2011-01-06
BRPI1016257B8 (pt) 2021-05-25
CN105687111A (zh) 2016-06-22
RU2570731C2 (ru) 2015-12-10
BRPI1016257B1 (pt) 2021-03-16
BRPI1016257A2 (pt) 2016-07-12
JP2015134827A (ja) 2015-07-27
TW201102395A (en) 2011-01-16
CA2765852C (en) 2014-08-26
UY32758A (es) 2010-10-29
AU2010266120A1 (en) 2012-02-02
KR101541823B1 (ko) 2015-08-04
US20130331385A1 (en) 2013-12-12
US20150328229A1 (en) 2015-11-19
JP2012532115A (ja) 2012-12-13
CL2011003327A1 (es) 2013-01-25
AR077372A1 (es) 2011-08-24
TWI460181B (zh) 2014-11-11
US8536167B2 (en) 2013-09-17
US9993483B2 (en) 2018-06-12
US20110003803A1 (en) 2011-01-06
EP2448587A1 (en) 2012-05-09
KR20120114211A (ko) 2012-10-16
ZA201109492B (en) 2013-03-27
ES2694775T3 (es) 2018-12-27
JP5784012B2 (ja) 2015-09-24
MX2012000136A (es) 2012-02-08
CN102470139A (zh) 2012-05-23
CA2765852A1 (en) 2011-01-06
RU2012103458A (ru) 2013-08-10
US9119859B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
US9993483B2 (en) Compositions and methods for treating ophthalmic, octic, or nasal infections
JP5563041B2 (ja) 眼、耳および鼻治療用の抗生物質組成物
US9504691B2 (en) Finafloxacin suspension compositions
US20150045739A1 (en) Method for treating otic infections after tympanostomy tube placement
US20170333441A1 (en) Compositions for treating microbial infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MERLION PHARMACEUTICALS, PTE., LTD.

Free format text: FORMER OWNER(S): ALCON RESEARCH, LTD.

PC Assignment registered

Owner name: MERLION PHARMACEUTICALS GMBH

Free format text: FORMER OWNER(S): MERLION PHARMACEUTICALS, PTE., LTD.

PC Assignment registered

Owner name: CUROFIN PHARMA GMBH

Free format text: FORMER OWNER(S): MERLION PHARMACEUTICALS GMBH